Effects of addition of fenofibrate in high risk patients with combined hyperlipidemia not controlled by pravastatin

被引：0
|
作者：
Ducobu, J.
Farnier, M.
Bryniarshi, L.
机构：
[1] CHU Tivoli, La Louviere, Belgium
[2] Point Med, Dijon, France
[3] Krakov, Pologne, Russia
来源：
DIABETES & METABOLISM | 2007年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
    Oikawa, Shinichi
    Yamashita, Shizuya
    Nakaya, Noriaki
    Sasaki, Jun
    Kono, Suminori
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (01) : 77 - 94
  • [42] Effects of low doses of atorvastatin in patients with familial combined hyperlipidemia
    Bottazzo, S
    Severi, G
    Fazzin, G
    ATHEROSCLEROSIS, 1998, 138 : S8 - S8
  • [43] Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe plus fenofibrate versus pravastatin monotherapy
    Grandi, Anna M.
    Nicolini, Eleonora
    Rizzi, Laura
    Caputo, Sara
    Annoni, Filippo
    Cremona, Anna M.
    Marchesi, Chiara
    Guasti, Luigina
    Maresca, Andrea M.
    Grossi, Paolo
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17
  • [44] Pravastatin is cost-effective in high-risk patients
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2006, 74 (10) : 1774 - +
  • [45] Medium/long-term combined treatment with simvastatin and fenofibrate in high-risk patients with mixed dyslipidemia
    Garrido, JA
    Pia, G
    FernandezAmeneiros, MJ
    GonzalezGonzalez, C
    Ameneiros, E
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 55 - 56
  • [46] The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide
    Achimastos, A
    Liberopoulos, E
    Nikas, S
    Bairaktari, E
    Miltiadous, G
    Tsimihodimos, V
    Elisaf, M
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) : 59 - 63
  • [47] Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia
    Kowalski, J
    Okopien, B
    Madej, A
    Zielinski, M
    Belowski, D
    Kalina, Z
    Herman, ZS
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (03) : 189 - 193
  • [48] Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia
    J. Kowalski
    B. Okopień
    A. Madej
    M. Zieliński
    D. Belowski
    Z. Kalina
    Z. S. Herman
    European Journal of Clinical Pharmacology, 2003, 59 : 189 - 193
  • [49] Comparative efficacy of fenofibrate/pravastatin/ezetimibe and simvastatin/ezetimibe therapies in type 2 diabetic patients with combined hyperlipidaemia and cardiovascular disease
    Farnier, M.
    Steinmetz, A.
    Csaszar, A.
    Retterstol, K.
    Dluzniewski, M.
    DIABETOLOGIA, 2010, 53
  • [50] Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia
    Arca, Marcello
    Montali, Anna
    Pigna, Giovanni
    Antonini, Roberto
    Antonini, Teresa Maria
    Luigi, Petrarnala
    Fraioli, Antonio
    Mastrantoni, Marco
    Maddaloni, Maura
    Letizia, Claudio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (11): : 1534 - 1541
12345